Notably, our results not only disagree with an increased expression of SELENOP in PAH, they rather indicate an inverse relation, i.e., decreasing SELENOP levels with aggravated disease states and a potential loss of SELENOP-related protection against oxidative stress in SSc that may contribute to PAH progression [57]. Here, SELENOP is linked to pulmonary arterial hypertension.